West Pharmaceutical Services (WST)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$339.97-0.81%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · WST
Price, fair value, and the multiples that frame it on the same time axis. Scroll over the price chart to zoom.
Daily closes. Earnings/event dots inline.
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $340 the market pays 40× p/e — above the 23× p/e peer median but in line with its own 41× history. That premium reflects a durable franchise our peer-anchored $262 fair value understates; treat the 'expensive vs peers' read with low confidence. Analysts target $365–$447. Note: our $262 fair value sits below the entire analyst range ($365–$447). The flat-multiple read looks rich, but earnings are inflecting up — trailing growth is accelerating and forward estimates confirm — so we've softened our read rather than brand an accelerating name expensive. Even the durable-growth case — current growth held at sustainable margins — values it at about $308, at or below today's price, so you're paying beyond even the growth case. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Score 100 = cheapest in the cohort, 0 = richest. Bars are filled left-to-right based on the peer-relative score (or PEG/self-history where shown).
Each method's implied share price per horizon. Provisional rows use a projected (historical-CAGR) growth input rather than analyst or management guidance.
| Method | Horizon | Est. price | Multiple | Per-share input | EPS source | Confidence |
|---|---|---|---|---|---|---|
| analyst target | 12M | $405.00 | — | — | Analyst | high |
| dcf fcfe | 12M | $114.66 | — | — | Hist. CAGR | high |
| dcf fcff | 12M | $120.74 | — | — | Hist. CAGR | high |
| graham number | 12M | $89.56 | — | — | TTM | high |
| Peer EV/EBITDA |
A “consensus-then vs. actual-now” overlay is on the way — what our valuation estimate said on a past date versus where the price actually landed.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
$365.00 – $447.00 (median $405.00) · 6 analysts · as of 2026-07-27
No fragility gates fired. Regime (Mania) does not concentrate fragility.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
At today's price the business can't be justified by any reasonable horizon of the forecast growth; the price already runs past what the model can underwrite. These describe the expectations embedded in the price, not a forecast of the move. Reverse-DCF base: $5.34/sh owner earnings.
Looks more expensive than peers.
Around its own typical valuation.
Trailing four: 2025-Q2, 2025-Q3, 2026-Q1, 2026-Q2
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
| 12M |
| $179.49 |
| 14.7 |
| 11.97 |
| TTM |
| high |
| Peer P/FCF | 12M | $161.89 | 26.4 | 6.13 | TTM | high |
| Peer P/E | 12M | $198.79 | 23.4 | 8.50 | TTM | high |
| Peer P/S | 12M | $141.23 | 3.0 | 46.66 | TTM | high |
| PEG | 12M | $271.32 | 31.9 | 8.50 | TTM | high |
| residual income | 12M | $61.88 | — | — | TTM | high |
| Own P/E history | 12M | $351.45 | 41.3 | 8.50 | TTM | high |
| triangulated | 12M | $218.91 | 23.4 | 9.36 | Triangulated | high |
| Peer P/FCF | 3Y | $178.25 | 26.4 | 6.75 | Hist. CAGR(prov.) | medium |
| Peer P/E | 3Y | $232.88 | 23.4 | 9.96 | Analyst | medium |
| Peer P/S | 3Y | $151.80 | 3.0 | 50.15 | guidance | medium |
| PEG | 3Y | $317.85 | 31.9 | 9.96 | Analyst | medium |
| Own P/E history | 3Y | $411.71 | 41.3 | 9.96 | Analyst | medium |
| Peer P/FCF | 5Y | $190.07 | 26.4 | 7.19 | Hist. CAGR(prov.) | high |
| Peer P/E | 5Y | $232.28 | 23.4 | 9.93 | Analyst | high |
| Peer P/S | 5Y | $151.41 | 3.0 | 50.02 | guidance | high |
| PEG | 5Y | $317.03 | 31.9 | 9.93 | Analyst | high |
| Own P/E history | 5Y | $410.65 | 41.3 | 9.93 | Analyst | high |